Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 16/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.46 |
| ▸ | HTR2B | P41595 | 5/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.46 |
| ▸ | HRH1 | P35367 | 4/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6460118 | 1.00 | MCHR1 (0.47) | MCHR1ADRA2AHTR2BADRA1AHRH1 | |
| SCHEMBL6459022 | 0.93 | MCHR1 (0.46) | MCHR1ADRA2AHTR2BADRA1AHRH1 | |
| SCHEMBL6459031 | 0.93 | MCHR1 (0.46) | MCHR1ADRA2AHTR2BADRA1AHRH1 | |
| SCHEMBL6462879 | 0.91 | MCHR1 (0.46) | MCHR1ADRA2AHTR2BADRA1AHRH1 | |
| SCHEMBL6462870 | 0.91 | MCHR1 (0.46) | MCHR1ADRA2AHTR2BADRA1AHRH1 | |
| SCHEMBL6457560 | 0.87 | MCHR1 (0.46) | MCHR1ADRA2AHTR2BADRA1AHRH1 | |
| SCHEMBL6457555 | 0.87 | MCHR1 (0.46) | MCHR1ADRA2AHTR2BADRA1AHRH1 | |
| SCHEMBL6460471 | 0.87 | MCHR1 (0.53) | MCHR1ADRA2AHTR2BADRA1AHRH1 | |
| SCHEMBL6880143 | 0.87 | MCHR1 (0.47) | MCHR1ADRA2AHTR2BADRA1AHRH1 | |
| SCHEMBL6460459 | 0.87 | MCHR1 (0.53) | MCHR1ADRA2AHTR2BADRA1AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | claimed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | claimed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | MCHR1 2/4885ADRA2A 117/4885HTR2B 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.